RAPT Therapeutics, Inc. (RAPT)
- Previous Close
8.00 - Open
8.02 - Bid 7.89 x 100
- Ask 7.92 x 100
- Day's Range
7.81 - 8.07 - 52 Week Range
6.86 - 27.35 - Volume
291,548 - Avg. Volume
1,358,788 - Market Cap (intraday)
278.398M - Beta (5Y Monthly) 0.47
- PE Ratio (TTM)
-- - EPS (TTM)
-3.05 - Earnings Date May 9, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
23.13
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company
www.rapt.comRecent News: RAPT
Performance Overview: RAPT
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RAPT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RAPT
Valuation Measures
Market Cap
274.92M
Enterprise Value
122.96M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.87
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-0.98
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-36.13%
Return on Equity (ttm)
-59.56%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-116.8M
Diluted EPS (ttm)
-3.05
Balance Sheet and Cash Flow
Total Cash (mrq)
158.86M
Total Debt/Equity (mrq)
4.70%
Levered Free Cash Flow (ttm)
-54.19M
Research Analysis: RAPT
Company Insights: RAPT
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: RAPT
Daily – Vickers Top Buyers & Sellers for 10/20/2021
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 10/18/2021
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 04/14/2021
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.